Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€334.15

€334.15

-1.340%
-4.55
-1.340%
€332.27
 
18:55 / Tradegate WKN: 867900 / Symbol: AMGN / Name: Amgen / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Amgen Inc. is only available for our menbers.
Not a member yet? Sign up for free!

Financial data and news for Amgen

sharewise wants to provide you with the best news and tools for Amgen, so we directly link to the best financial data sources.

News

Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent PressurePhoto, wide shot, wide-angle lens,  Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png
Amgen Eyes 2026 ‘Springboard’ as Growth Drugs Offset Patent Pressure

Key Points

Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies ConferencePhoto, wide shot, wide-angle lens,  Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference

Key Points

Zai Lab Q1 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
Zai Lab Q1 Earnings Call Highlights

Zai Lab (NASDAQ:ZLAB) reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients: https://g.foolcdn.com/editorial/images/880088/amgen.png
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Amgen (NASDAQ: AMGN) is betting that the convenience of its weight loss treatment will make it a winner, and it might be right. Its candidate MariTide is a monthly injection that aims to directly

How Safe Is Amgen's Dividend?: https://g.foolcdn.com/editorial/images/876180/amgen-logo.png
How Safe Is Amgen's Dividend?

Amgen (NASDAQ: AMGN) has been grabbing headlines lately, and not always for the right reasons. The company is currently engaged in a battle with the U.S. Food and Drug Administration (FDA), which

Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/7089e9c275d4f6f9668a8e5e172ac46be0ed0aaa-1200x800.png?w=800&q=75&fit=max&auto=format
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Does the established stability of a pharmaceutical giant outweigh the explosive growth potential of a specialized cancer fighter? Investors choosing between Amgen (NASDAQ:AMGN) and Iovance

Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?: https://cdn.content.foolcdn.com/images/1umn9qeh/production/2d10dfb318519977a677bcb00f3da6d28e64e4b0-1200x800.png?w=800&q=75&fit=max&auto=format
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?

Deciding between a pharmaceutical giant and a niche medical innovator depends on your risk tolerance. Amgen (NASDAQ:AMGN) and NovoCure (NASDAQ:NVCR) offer vastly different paths to potential growth

Amgen: A Biotech Giant's Path to Recovery and Growth: https://g.foolcdn.com/editorial/images/871758/maxresdefault.jpg
Amgen: A Biotech Giant's Path to Recovery and Growth

Explore the exciting world of Amgen (NASDAQ: AMGN) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market

2 Dividend Stocks to Double Up On Right Now: https://g.foolcdn.com/editorial/images/868140/amgen-and-merck-logos.png
2 Dividend Stocks to Double Up On Right Now

Equity markets have handled the economic uncertainty and geopolitical instability we have seen in recent months admirably well so far. The S&P 500 is up 7% year to date. However, we may not be

Better Weight Loss Stock: Novo Nordisk Vs. AmgenPhoto, wide shot, wide-angle lens, soft focus,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Hiroshi Sugimoto: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-pKgbwxVSbyTCu0UzPNe8NL8D.png?st=2023-05-04T16%3A02%3A58Z&se=2023-05-04T18%3A02%3A58Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-05-04T12%3A13%3A51Z&ske=2023-05-05T12%3A13%3A51Z&sks=b&skv=2021-08-06&sig=%2BhYssNp3W0HiZMxCV64XVELyP8stYUjFhgUVfPrTLyg%3D
Better Weight Loss Stock: Novo Nordisk Vs. Amgen

The weight-loss market has become one of the most active therapeutic areas in the pharmaceutical industry over the past few years. And based on analyst projections, it will continue growing at a